CEMI

Chembio Diagnostics, Inc. (CEMI) | Rumor.io

Chembio Diagnostics

CEMI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CEMI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 27

Chembio Diagnostics, Inc. ($CEMI) has been acquired by Biosynex, with the merger expected to go through despite initial concerns about the tender offer.
Shareholders who did not accept the tender offer may still be affected by the merger, but the specifics are unclear.
Credit Advisors Ll Perceptive has acquired 39,506 shares of Chembio Diagnostics, Inc. ($CEMI) stock, indicating ongoing interest in the company.

Generated by AI

Sentiment

Of the messages about CEMI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +30
Bearish	—	—	—	0% -30

Bullish· Jan 13

$CEMI is poised to break out and head higher, with a potential target of $0.50 or beyond.
Chembio Diagnostics, Inc. is expected to see a strong close, with the chart indicating a clear breakout flag.
A positive earnings report (ER) and FDA approval or waiver could lead to significant gains for $CEMI, potentially sending the stock price soaring.

Bearish· Feb 1

The company's management may prioritize a takeover or bankruptcy over selling the company for a lower price, potentially leaving shareholders with minimal returns.
The company's CFO, Larry, may be responsible for the company's downfall, and the takeover may be an attempt to shift blame or escape accountability.
The company's FDA approval prospects are uncertain, and even if the takeover is successful, the stock price may plummet to as low as $0.15-$0.20 per share, making the current $0.45 price seem like a good deal.

Generated by AI

Topics

Of the messages about CEMI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Aug 5

Chembio Diagnostics (CEMI) reported Q2 total revenue of $6.5 million, a 26% increase from the prior year period.
Net product sales for Q2 were $3.9 million, a 4% increase from the prior year period, while government grant, license and royalty, and R&D revenue increased 92% to $2.5 million.
The company reported a Q2 loss of $0.45 per share, missing the analyst consensus estimate of a loss of $0.27 per share by 66.67%.

Announcements· Jan 31

Chembio Diagnostics, Inc. ($CEMI) has been acquired by Biosynex in an all-cash transaction valued at $17.2 million, with a premium of 27% compared to the closing price on January 30, 2023.
The acquisition is subject to certain conditions, including the tender of shares representing at least a majority of the total number of Chembio's outstanding shares, and is expected to close in the first quarter of 2023.
The transaction was unanimously approved by the Boards of Directors of both companies, and the Board of Directors of Chembio intends to recommend the transaction to Chembio's stockholders.

Technical Analysis· Aug 3

$CEMI has resistance near $1.21, $1.28, $1.37, $1.46, and $1.57, and support is near $1.08, $1, $0.90, and $0.79.
A break over $1.27 could send $CEMI flying for a range of $1.40 plus, with an exit set at $1.08.
$CEMI is trending over the EMAs, but a drop is also possible, with a current price of $1.33 and a 10.8% gain so far.

Generated by AI

Community

Of the messages about CEMI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	64.29%
Newcomers	—	—	—	35.71%

Regulars· Feb 1

Chembio Diagnostics, Inc. (CEMI) has been acquired by Biosynex for $0.45 per share, with the deal announced through a definitive acquisition agreement.
The acquisition has led to a significant price increase, with CEMI stock rising by $0.09 (24.33%) to $0.45.
Halper Sadeh LLC is investigating whether the sale of Chembio Diagnostics, Inc. is fair to shareholders, with a possible implication that the acquisition price may be undervalued.

Newcomers· Sep 2

New traders are looking at Chembio Diagnostics, Inc. ($CEMI) as a potential winner, with one user expecting it to "explode" in value.
The company's stock has seen a significant increase in call volume, with 126 calls made, which is 84,000% above the 30-day average.
Chembio Diagnostics, Inc. ($CEMI) shares have risen 18.75% after the company was granted a government contract, and also saw a 5.5% increase on September 1.

Generated by AI

Also Discussed

Investors talking about CEMI also mention

#	Name	Attention
1	NanoVibronix, Inc.NAOV	0%0
2	MediaCo Holding Inc. Class A Common StockMDIA	0%0
3	XELA - Exela Technologies, Inc.	——
4	Xenetic Biosciences, Inc.XBIO	0%new
5	NRx Pharmaceuticals, Inc.NRXP	0%-0.01
6	TKAT - Takung Art Co., Ltd.	——
7	TROOPS Inc.TROO	0%0
8	ERYP - ERYTECH Pharma S.A.	——
9	WHLM - Wilhelmina International, Inc.	——
10	CARV - Carver Bancorp, Inc.	——